Southwest Oncology Group 1501 Study Targets Silo Between Cardiology & Oncology

Mar 25, 2019 | Cardiology, Oncology, Southwest Oncology Group

Cancer Drug

Justin Floy of the Cancer Letter reports that cancer research reveals the promise of bridging silos on multiple levels.  Southwest Oncology Group is launching its S1501 trial, an active NCI-funded study evaluating the efficacy of carvedilol in reducing cardiac dysfunction in metastatic HER-2 overexpressing breast cancer patients.  Follow the link to learn more about how SWOG is bringing cardiology & oncology therapy and treatments together.

0 Comments

Pin It on Pinterest